Uric acid in metabolic syndrome: From an innocent bystander to a central player

• Uric acid is a novel risk factor for obesity, diabetes, and cardiorenal disease.
• It is still premature to lower uric acid for reducing metabolic and cardiovascular disease.
• Trials are needed to test if lowering uric acid can be beneficial in the prevention.

Uric acid, once viewed as an inert metabolic end-product of purine metabolism, has been recently incriminated in a number of chronic disease states, including hypertension, metabolic syndrome, diabetes, non-alcoholic fatty liver disease, and chronic kidney disease. Several experimental and clinical studies support a role for uric acid as a contributory causal factor in these conditions. Here we discuss some of the major mechanisms linking uric acid to metabolic and cardiovascular diseases. At this time the key to understanding the importance of uric acid in these diseases will be the conduct of large clinical trials in which the effect of lowering uric acid on hard clinical outcomes is assessed. Elevated uric acid may turn out to be one of the more important remediable risk factors for metabolic and cardiovascular diseases.